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Success of rotavirus vaccination in Africa: good news and 
remaining questions
The study by Fidele Ngabo and colleagues in The Lancet 
Global Health1 shows the feasibility of the successful 
introduction and large eﬀ ect of rotavirus vaccination 
in Rwanda. The ﬁ ndings are a tribute not only to 
rotavirus vaccination but also to the RotaTeq (so-called 
pentavalent or RV5) vaccine because Rwanda has used 
this vaccine exclusively in its immunisation programme. 
Several African countries have introduced rotavirus 
vaccination using the human rotavirus vaccine Rotarix 
and good eﬀ ectiveness has been reported from South 
Africa2 and Malawi.3
The real-life eﬀ ectiveness of RotaTeq in Rwanda 
was recorded in several ways and is convincing. After 
the introduction of rotavirus vaccination in 2012, 
admittance to hospital for gastroenteritis decreased 
by 49% in 2013, and 48% in 2014, and admittance to 
hospital for rotavirus in the hospitals doing speciﬁ c 
rotavirus diagnosis decreased by 61% and 70% in the 
same period. The eﬀ ectiveness is actually in line with 
the available prelicensure eﬃ  cacy data for RotaTeq in 
Kenya (83%) and Ghana (65%) against severe rotavirus 
gastroenteritis severity score (the Vesikari score) 
of 11/20.4,5
It is impressive that, according to the report of Ngabo 
and colleagues, Rwanda has reached a coverage rate of 
98–99% for rotavirus vaccination. Although it does not 
specify whether this meant all three doses, the study shows 
that RotaTeq vaccination is compatible with the Expanded 
Programme on Immunization (EPI) dosing at 6, 10, and 
14 weeks of age and that a three-dose vaccine (and not 
only two-dose Rotarix) can successfully be given in Africa. 
Three doses might be better than two because durable 
immunity against rotavirus depends on the number of hits, 
whether vaccination or natural infection,6 although the 
two-dose Rotarix has also shown good protection in Africa.
The report contains no information about rotavirus 
serotypes in Rwanda. This is not that important 
though because for practical purposes surveillance of 
rotavirus serotypes is becoming obsolete as it has been 
convincingly shown that the eﬃ  cacy and eﬀ ectiveness 
of rotavirus vaccines against severe rotavirus gastro-
enteritis are not serotype-speciﬁ c. Thus, the pentavalent 
and monovalent vaccines are at the same start line.7 
As an example, the 49% eﬃ  cacy of Rotarix in Malawi 
was the same against various rotavirus G-types that 
were recorded during the trial.5 If the performance 
of rotavirus vaccines in Africa is not as good as in 
developed countries, it is not because there are more 
diverse rotavirus serotypes circulating in Africa.
Although the eﬀ ectiveness of rotavirus vaccine in 
Rwanda is high and is promising, the eﬀ ectiveness 
is still less than in developed countries. For example, 
in Finland, with equally high coverage, the eﬀ ect of 
rotavirus vaccination has been an 88% reduction of 
admittances to hospital for rotavirus gastroenteritis, 
with most of the remaining cases occurring in older 
children who have been too old to be vaccinated in 
the programme, and very few breakthrough cases of 
severe rotavirus gastroenteritis in vaccinated children, 
and even those mostly in partially vaccinated children.8 
Such information from Rwanda (and other African 
countries) is missing, and future studies should address 
the eﬀ ectiveness of RotaTeq vaccine after complete and 
incomplete series of vaccinations.
An interesting ﬁ nding in the study of Ngabo and 
colleagues was that, after a huge drop in the number 
of admittances to hospital for rotavirus in 2013, there 
was no further fall the next year. As the researchers 
discuss, this ﬁ nding might herald the beginning of 
a biennial pattern of rotavirus activity in Africa after 
universal rotavirus vaccination—a phenomenon that 
has been seen in the USA for several years.9 Another 
epidemiological change in the USA has been a shift of the 
rotavirus epidemic season towards a later onset. Perhaps 
the data from Rwanda can be read to suggest that this 
might be also happening in an African country that has a 
very clear seasonal pattern of rotavirus activity.
Altogether, the experience of the ﬁ rst 2 years of 
rotavirus vaccination in Rwanda can be summarised 
as a success. But does this success come at a price? The 
present report does not even mention intussusception 
or give any information about compliance with the 
EPI schedule. The WHO position towards rotavirus 
vaccination in Africa has been that in the interest of 
better coverage the timing of the ﬁ rst dose can be 
extended up to 6 months of age.10 It is recognised that 
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this could increase the risk of intussusception. It would 
be important to document how well African countries 
can adhere to the recommended EPI schedule of 6, 
10, and 14 weeks, because, if adhered to, such early 
administration could rather decrease or even minimise 
the risk. The report from Rwanda does not address this 
point, and further information is awaited.
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